BRAF D594VBRAF L597RARAF S214CKRAS G12/G13BRAF TRIM24-BRAFBRAF L597SBRAF L597QBRAF K601EBRAF L597VBRAF D594GBRAF PPFIBP2-BRAFBRAF KIAA1549-BRAFBRAF ZKSCAN1-BRAFBRAF PAPSS1-BRAFNRAS MUTATIONKRAS MUTATIONDUSP6 EXPRESSIONBRAF MUTATIONGNAQ MUTATIONGNA11 MUTATIONBRAF V600chr7:g.140453136A>T (BRAF:p.V600E)RASA1 LOSS-OF-FUNCTIONBRAF N486_P490delBRAF NRF1-BRAF
P3354
P3355
P3781
Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid TumorsDabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryInvestigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerTrametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaDabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNeoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive MelanomaTrametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast CancerTreatment of NF1-related Plexiform Neurofibroma With TrametinibTrametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-typeDabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF MutationEGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and T790M-positive Resistance to EGFR TKI TherapyTrametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung CancerStudy of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS MutationGSK1120212 in Surgically Resectable Oral Cavity Squamous Cell CancerCombination Study of GSK1120212 With Gemcitabine in Subjects With Solid TumorsA Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor CancersAbsolute Bioavialability of GSK1120212An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung CancerStudy of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-sEfficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal MelanomaA Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive TumorsStudy of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic CancerDabrafenib + Trametinib + PDR001 In Colorectal CancerCombination of Alpelisib and Trametinib in Progressive Refractory MeningiomasStudy of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerTrametinib and TAS-102 in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by SurgeryPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal CancerDabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaTrametinib in Treating Patients With Advanced Cancer With or Without Hepatic DysfunctionA Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaTrial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung CancerDabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 MutationsCAcTUS - Circulating Tumour DNA Guided SwitchTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular CancerTrametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryMOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMASDabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
P4844
Panitumumab / Dabrafenib / Trametinib combination therapyTrametinib / Ponatinib combination therapyDabrafenib / Trametinib combination therapyPanitumumab / Trametinib combination therapyTrametinib / Imatinib combination therapyTrametinib / PD0325901 combination therapytrametinib / gemcitabine combination therapyNon-small cell lung cancertrametinib / vemurafenib / dabrafenib combination therapytrametinib / docetaxel trihydrate combination therapytrametinib / metformin combination therapyomipalisib / trametinib combination therapyafatinib / trametinib combination therapypemetrexed / trametinib / docetaxel trihydrate combination therapy
P527
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesionsIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaInhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinibA phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.MEK and the inhibitors: from bench to bedside.Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorConcurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.Cutaneous effects of BRAF inhibitor therapy: a case series.Resistance to BRAF-targeted therapy in melanoma.Trametinib (GSK1120212) in the treatment of melanoma.Dabrafenib in the treatment of advanced melanoma.Trametinib: first global approval.Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells.Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.Latest approved therapies for metastatic melanoma: what comes next?Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.Trametinib for the treatment of melanoma.Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid CarcinomaOveractive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial SarcomaAgents to treat mutant lung cancerResults from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancermutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic responseThe Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung CancerStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Trametinib
@de
Trametinib
@nb
Trametinib
@sh
Trametinib
@sr
Trametinib
@vi
trametinib
@cs
trametinib
@en
trametinib
@nn
トラメチニブ
@ja
曲美替尼
@zh
type
label
Trametinib
@de
Trametinib
@nb
Trametinib
@sh
Trametinib
@sr
Trametinib
@vi
trametinib
@cs
trametinib
@en
trametinib
@nn
トラメチニブ
@ja
曲美替尼
@zh
altLabel
GSK 1120212
@en
GSK1120212
@en
GSK1120212B
@en
GSK212
@en
JTP 74057
@en
Mekinist®
@en
TMT212
@en
Trametinib
@en
Trametinibum
@en
Tramétinib
@en
prefLabel
Trametinib
@de
Trametinib
@nb
Trametinib
@sh
Trametinib
@sr
Trametinib
@vi
trametinib
@cs
trametinib
@en
trametinib
@nn
トラメチニブ
@ja
曲美替尼
@zh